Gilead Sciences, Inc. (GILD)
Gilead Sciences_Rating Upgrade Warranted On HIV Division Strength (Buy)
Gilead Sciences Non-GAAP EPS of $2.47 beats by $0.33, revenue of $7.77B beats by $310M
(Earnings Call Insights) Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum
What To Expect From Gilead In Q3 2025 (StrongBuy)
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run (StrongBuy)
